{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:40:29Z","timestamp":1792680029185,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"am","delay-in-days":283,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH Library","doi-asserted-by":"publisher","award":["R01-CA260902"],"award-info":[{"award-number":["R01-CA260902"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH Library","doi-asserted-by":"publisher","award":["P50CA228991"],"award-info":[{"award-number":["P50CA228991"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002300","name":"Rivkin Center for Ovarian Cancer","doi-asserted-by":"publisher","award":["R01-CA260902"],"award-info":[{"award-number":["R01-CA260902"]}],"id":[{"id":"10.13039\/100002300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014008","name":"Ovarian Cancer Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013401","name":"Ovarian Cancer Research Fund Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","award":["P50CA228991"],"award-info":[{"award-number":["P50CA228991"]}],"id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ygyno.2024.04.001","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T19:00:30Z","timestamp":1712775630000},"page":"77-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Adoptive T cell therapy for ovarian cancer"],"prefix":"10.1016","volume":"186","author":[{"given":"Sarah B.","family":"Gitto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chibuike J.N.","family":"Ihewulezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Daniel J.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.04.001_bb0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0010","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ygyno.2017.03.510","article-title":"T-cell target antigens across major gynecologic cancers","volume":"145","author":"Rodriguez-Garcia","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0020","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0025","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0030","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0035","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ccell.2022.03.008","article-title":"Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells","volume":"40","author":"Anadon","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0040","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","article-title":"CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor","volume":"20","author":"Ye","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0050","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1186\/s12885-017-3585-x","article-title":"Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer","volume":"17","author":"James","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0055","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/modpathol.2008.191","article-title":"Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss","volume":"22","author":"Clarke","year":"2009","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0060","article-title":"Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer","volume":"3","author":"Ovarian Tumor Tissue Analysis C","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0065","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0070","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0075","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","article-title":"PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer","volume":"141","author":"Webb","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0080","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.18632\/oncotarget.6429","article-title":"Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma","volume":"7","author":"Darb-Esfahani","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0085","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ygyno.2016.07.105","article-title":"Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer","volume":"143","author":"Santoiemma","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0090","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/IGC.0000000000000672","article-title":"Combined immunoscore of CD103 and CD3 identifies long-term survivors in high-grade serous ovarian cancer","volume":"26","author":"Bosmuller","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2024.01.029","article-title":"CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival","volume":"184","author":"Tubridy","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0100","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0105","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41467-020-15315-8","article-title":"Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer","volume":"11","author":"Farkkila","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0110","first-page":"9","article-title":"Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates","author":"Liao","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0115","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","article-title":"Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study","volume":"26","author":"Lampert","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0120","doi-asserted-by":"crossref","first-page":"1659093","DOI":"10.1080\/2162402X.2019.1659093","article-title":"Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients","volume":"9","author":"Gide","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0125","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41416-019-0634-z","article-title":"Spatial proximity between T and PD-L1 expressing cells as a prognostic biomarker for oropharyngeal squamous cell carcinoma","volume":"122","author":"Tsakiroglou","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0130","first-page":"262","article-title":"A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2","volume":"100","author":"Rosenberg","year":"1986","journal-title":"Surgery"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0135","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0140","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","article-title":"Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future","volume":"29","author":"Betof Warner","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0145","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0150","first-page":"1934","article-title":"Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer","volume":"51","author":"Aoki","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0155","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00002371-199410000-00004","article-title":"Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial","volume":"16","author":"Freedman","year":"1994","journal-title":"J. Immunother. Emphasis Tumor Immunol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0160","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1502905","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study","volume":"7","author":"Pedersen","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0165","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-10-1297","article-title":"CD8+ enriched \u201cyoung\u201d tumor infiltrating lymphocytes can mediate regression of metastatic melanoma","volume":"16","author":"Dudley","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0170","first-page":"13","article-title":"CD137 as an attractive T cell co-stimulatory target in the TNFRSF for immuno-oncology drug development","author":"Hashimoto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0175","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00262-019-02402-z","article-title":"Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy","volume":"68","author":"Sakellariou-Thompson","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0180","first-page":"12","article-title":"Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma","author":"Amaria","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0185","doi-asserted-by":"crossref","first-page":"1256491","DOI":"10.3389\/fimmu.2023.1256491","article-title":"Signaling via a CD28\/CD40 chimeric costimulatory antigen receptor (CoStAR), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes","volume":"14","author":"Kalaitsidou","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0190","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1089\/hum.2007.0171","article-title":"Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2","volume":"19","author":"Heemskerk","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0195","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3389\/fimmu.2017.00908","article-title":"A novel method to generate and expand clinical-grade, genetically modified, tumor-infiltrating lymphocytes","volume":"8","author":"Forget","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0200","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163096","article-title":"Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR\/Cas9 screens","volume":"133","author":"Schlabach","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0205","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2014.7","article-title":"Clinical application of genetically modified T cells in cancer therapy","volume":"3","author":"Kershaw","year":"2014","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0210","first-page":"8","article-title":"Development of therapeutic vaccines for ovarian cancer","author":"Chow","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0215","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/2326-6066.CIR-22-0444","article-title":"Feasibility and safety of personalized, multi-target, adoptive cell therapy (IMA101): first-in-human clinical trial in patients with advanced metastatic cancer","volume":"11","author":"Tsimberidou","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0220","first-page":"14","article-title":"Dendritic cell vaccines: a promising approach in the fight against ovarian cancer","author":"Caro","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0225","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40425-016-0137-x","article-title":"Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial","volume":"4","author":"Gray","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0230","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ygyno.2021.07.003","article-title":"Dendritic cell-based immunotherapy (DCVAC\/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): a randomized, open-label, phase 2 trial","volume":"162","author":"Cibula","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0235","first-page":"10","article-title":"Safety and efficacy of dendritic cell-based immunotherapy DCVAC\/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial","author":"Rob","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0240","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1158\/1078-0432.CCR-21-4413","article-title":"An autologous dendritic cell vaccine promotes anticancer immunity in patients with ovarian cancer with low mutational burden and cold tumors","volume":"28","author":"Fucikova","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0245","first-page":"10","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","author":"Tanyi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0250","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41541-021-00297-5","article-title":"Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer","volume":"6","author":"Tanyi","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0255","first-page":"1410","article-title":"A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer","volume":"4","author":"Bobisse","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0260","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1158\/1078-0432.CCR-17-2499","article-title":"Folate receptor alpha peptide vaccine generates immunity in breast and ovarian cancer patients","volume":"24","author":"Kalli","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0265","doi-asserted-by":"crossref","first-page":"12837","DOI":"10.1073\/pnas.0703342104","article-title":"Vaccination with an NY-ESO-1 peptide of HLA class I\/II specificities induces integrated humoral and T cell responses in ovarian cancer","volume":"104","author":"Odunsi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0270","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/jamaoncol.2015.2736","article-title":"Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial","volume":"1","author":"Heery","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0275","article-title":"Biomaterial-based in situ cancer vaccines","author":"Bo","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0280","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0285","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1200\/JCO.2023.41.16_suppl.2547","article-title":"Safety and efficacy of sleeping beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study","volume":"41","author":"Morelli","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0290","doi-asserted-by":"crossref","first-page":"1121973","DOI":"10.3389\/fimmu.2023.1121973","article-title":"PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer","volume":"14","author":"van Amerongen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0295","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J. Immunother."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0300","first-page":"3","article-title":"Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy","author":"Yossef","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0305","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1038\/s41467-021-24562-2","article-title":"Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting","volume":"12","author":"Bear","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0310","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ygyno.2023.08.007","article-title":"The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: opportunities for novel therapeutic approaches","volume":"177","author":"Nasioudis","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0315","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1674","article-title":"CAR T-cell therapy in hematologic malignancies: a voyage in progress","volume":"107","author":"Holstein","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0320","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1158\/1078-0432.67.11.1","article-title":"HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage","volume":"11","author":"Vitale","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0325","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0330","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s002620050415","article-title":"Tumor-specific T-bodies: towards clinical application","volume":"45","author":"Eshhar","year":"1997","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0335","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","article-title":"Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo","volume":"1","author":"Lanitis","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0340","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0345","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin\u2019s lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0350","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0355","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0360","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1479-5876-10-157","article-title":"A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer","volume":"10","author":"Kandalaft","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0365","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.tips.2015.11.004","article-title":"Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors","volume":"37","author":"Harris","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0370","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fonc.2019.00176","article-title":"The emergence of universal immune receptor T cell therapy for cancer","volume":"9","author":"Minutolo","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0375","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0380","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.ccell.2022.11.006","article-title":"Expression of inducible factors reprograms CAR-T cells for enhanced function and safety","volume":"40","author":"Smole","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0385","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hon.3163_6","article-title":"Fourth generation HUCART19-IL18 produces druable responses in lymphoma patients previously relapsed\/refractory to anti-CD19 CAR T-cell therapy","volume":"41","author":"Svoboda","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0390","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.745286","article-title":"Engineered removal of PD-1 from the surface of CD19 CAR-T cells results in increased activation and diminished survival","volume":"8","author":"Kalinin","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0395","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0400","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0405","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abk1900","article-title":"T(STEM)-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models","volume":"15","author":"Meyran","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0410","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.coi.2021.07.002","article-title":"Safety switches for adoptive cell therapy","volume":"74","author":"Sahillioglu","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0415","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1600-065X.2006.00455.x","article-title":"Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self","volume":"214","author":"Ruggeri","year":"2006","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0420","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0425","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/14653249.2010.515582","article-title":"A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer","volume":"13","author":"Geller","year":"2011","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0430","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/2326-6066.CIR-15-0118","article-title":"Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors","volume":"4","author":"Yang","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0435","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3892\/mco.2017.1230","article-title":"Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: a case report","volume":"6","author":"Xie","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0440","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0445","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ygyno.2022.03.013","article-title":"Adoptive cell therapy in gynecologic cancers: a systematic review and meta-analysis","volume":"165","author":"Son","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0450","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1509819","article-title":"PD-L1 blockade enhances anti-tumor efficacy of NK cells","volume":"7","author":"Oyer","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ygyno.2024.04.001_bb0455","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0460","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Rodriguez-Garcia","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0465","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Naive T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0470","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/bloodadvances.2020001797","article-title":"Lingering effects of chemotherapy on mature T cells impair proliferation","volume":"4","author":"Das","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ygyno.2024.04.001_bb0475","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","article-title":"Total costs of chimeric antigen receptor T-cell immunotherapy","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:58:12Z","timestamp":1777474692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824001860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":95,"alternative-id":["S0090825824001860"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.04.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adoptive T cell therapy for ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}